4.3 Article

The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette

期刊

SEMINARS IN HEMATOLOGY
卷 54, 期 4, 页码 184-188

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminhematol.2017.08.003

关键词

Social media; Twitter; Disease-specific hashtag; Medical conferences

资金

  1. MD Anderson Cancer Center Support Grant [P30 CA016672]

向作者/读者索取更多资源

The use of social media, and in particular, Twitter, for professional use among healthcare providers is rapidly increasing across the world. One medical subspecialty that is leading the integration of this new platform for communication into daily practice and for information dissemination to the general public is the field of hematology/oncology. A growing amount of research in this area demonstrates that there is increasing interest among physicians to learn not only how to use social media for consumption of educational material, but also how to generate and contribute original content in one's interest/expert areas. One aspect in which this phenomenon has been highlighted is at the time of maximum new information presentation: at a major medical conference. Hematologists/oncologists are engaging regularly in one of the most common forms of social media, Twitter, during major medical conferences, for purposes of debate, discussion, and real-time evaluation of the data being presented. As interest has grown in this area, this article aims to review the new norms, practices, and impact of using Twitter at the time of medical conferences, and also explores some of the barriers and pitfalls that users are encountering in this emerging field. (C) 2017 Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma

Yazeed Sawalha, Tomas Radivoyevitch, Xuefei Jia, Katherine Tullio, Robert M. Dean, Brad Pohlman, Brian T. Hill, Matt Kalaycio, Navneet S. Majhail, Deepa Jagadeesh

Summary: Younger patients with private insurance and receiving treatment at academic facilities are more likely to undergo autologous stem cell transplantation for mantle cell lymphoma, which is associated with improved survival rates.

LEUKEMIA & LYMPHOMA (2022)

Letter Biophysics

Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation

Pranay Hegde, Lisa Rybicki, Sheila Serafino, Christina Ferraro, Matt Kalaycio, Ronald Sobecks, Aaron T. Gerds, Sharon Caroniti, Donna Corrigan, Kayla Giannetti, Jamie Elberson, Brittany Hodgeman, Jamie Starn, Jane Dabney, Linda McLellan, Navneet S. Majhail, Betty K. Hamilton

BONE MARROW TRANSPLANTATION (2022)

Letter Biophysics

Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation

Julia H. Joo, Sanghee Hong, Lisa A. Rybicki, Betty K. Hamilton, Navneet S. Majhail

BONE MARROW TRANSPLANTATION (2022)

Article Biophysics

Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis

Joseph E. Maakaron, Mei-Jie Zhang, Karen Chen, Sunil Abhyankar, Vijaya Raj Bhatt, Saurabh Chhabra, Najla El Jurdi, Sherif S. Farag, Fiona He, Mark Juckett, Marcos de Lima, Navneet Majhail, Marjolein van der Poel, Ayman Saad, Bipin Savani, Celalettin Ustun, Edmund K. Waller, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber, Daniel Weisdorf

Summary: A study on 1321 AML patients aged 60 and older found that age alone is not a barrier to successful HCT in CR1, and efforts should focus on minimizing residual disease and better donor selection.

BONE MARROW TRANSPLANTATION (2022)

Letter Biophysics

Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant

Pranay S. Hegde, Lisa Rybicki, Sheila Serafino, Laura Bernhard, Donna Corrigan, Faiz Anwer, Matt Kalaycio, Ronald M. Sobecks, Deepa Jagadeesh, Brian T. Hill, Robert M. Dean, Jack Khouri, Allison M. Winter, Brad Pohlman, Navneet S. Majhail, Betty K. Hamilton

BONE MARROW TRANSPLANTATION (2022)

Review Oncology

Prognostic Impact of Adiposity in Hematological Malignancies: A Systematic Review and Meta-analysis

Gabriel F. P. Aleixo, Michael Sheu, Saeid Mirzai, Navneet S. Majhail

Summary: This study found that hematological malignancy patients with low visceral adiposity have higher risks of mortality and disease progression, while patients with subcutaneous adipopenia have nearly 3 times greater mortality risk.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Letter Biophysics

Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

Agrima Mian, Wei Wei, Betty K. Hamilton, Allison M. Winter, Jack Khouri, Brad Pohlman, Aaron T. Gerds, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M. Dean, Ronald Sobecks, Paolo F. Caimi, Brian T. Hill, Navneet S. Majhail

BONE MARROW TRANSPLANTATION (2023)

Article Hematology

Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A. Kharfan-Dabaja, Navneet S. Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher Strouse, Sherif M. Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H. Vesole, Cindy H. Lee, Attaphol Pawarode, Usama Gergis, Kevin C. Miller, Leona A. Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson Jr, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji K. Kumar, Saad Z. Usmani

Summary: The use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT), has significantly improved the overall survival (OS) in multiple myeloma (MM) patients. However, the use of lenalidomide maintenance after auto-HSCT has been associated with an increased risk of second primary malignancies (SPM) and second hematological malignancies (SHM). This study evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in MM patients after auto-HSCT using registry data.

BLOOD ADVANCES (2023)

Article Hematology

Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships

Rahul Banerjee, Amar H. Kelkar, Urshila Durani, Theodora Anagnostou, Miki Nishitani, Kanwaldeep Mallhi, Navneet S. Majhail, Aaron C. Logan

Summary: Recent guidelines from the American Society for Transplantation and Cellular Therapy have aimed to establish expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. A survey was conducted to examine the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. The results showed that the fellowship training had a positive impact on participants' comfort with BMT/CT management and the majority would highly recommend this training to others.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

Sagar S. Patel, Sanghee Hong, Lisa Rybicki, Stephanie Farlow, Jane Dabney, Matt Kalaycio, Ronald Sobecks, Navneet S. Majhail, Betty K. Hamilton

Summary: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (HCT), causing significant physical and psychosocial symptoms. This pilot study aimed to assess the feasibility of using patient-reported outcome (PRO) measures to evaluate symptom burden and quality of life (QOL) in acute GVHD. The study utilized surveys from various PRO measures and found that patients with acute GVHD had lower QOL scores compared to those without or with mild GVHD. The PRO-CTCAE captured several common symptoms of acute GVHD. Challenges in implementing PRO measures in acute GVHD were identified. Further research is needed to make PROs feasible in this patient population.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S. L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala, Navneet S. Majhail

Summary: Survivors of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in stable remission do not have clinically meaningful worsening in physical functioning compared to the general population. However, they may experience distress related to health burden, uncertainty, and finances. Adherence to preventive care guidelines is high, but adherence to exercise and diet guidelines is relatively low.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Abraham S. Kanate, Navneet Majhail, Zachariah Defilipp, Binod Dhakal, Bhagirathbhai Dholaria, Betty Hamilton, Alex F. Herrera, Yoshihiro Inamoto, Tania Jain, Miguel -Angel Perales, Paul A. Carpenter, Mehdi Hamadani

Summary: The American Society for Transplantation and Cellular Therapy (ASTCT) has published guidelines on CAR-T therapy indications, categorizing them as standard of care and recommending only FDA-approved indications. These guidelines will be periodically updated based on new evidence.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors

Nosha Farhadfar, Michael T. Weaver, Zeina Al-Mansour, Jean C. Yi, Heather S. L. Jim, Alison W. Loren, Navneet S. Majhail, Victoria Whalen, Joseph Uberti, John R. Wingard, Debra Lynch Kelly, Karen L. Syrjala

Summary: The self-efficacy level of hematopoietic cell transplantation (HCT) survivors is associated with factors such as fatigue, depression, quality of life, and cancer-related distress. Lower self-efficacy is linked to higher levels of symptoms and distress, as well as lower quality of life. Therefore, improving self-efficacy in survivors is crucial for enhancing their recovery.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation

Sagar S. Patel, Kwang Woo Ahn, Manoj Khanal, Caitrin Bupp, Mariam Allbee-Johnson, Navneet S. Majhail, Betty K. Hamilton, Seth J. Rotz, Hasan Hashem, Amer Beitinjaneh, Hillard M. Lazarus, Maxwell M. Krem, Tim Prestidge, Neel S. Bhatt, Akshay Sharma, Shahinaz M. Gadalla, Hemant S. Murthy, Larisa Broglie, Taiga Nishihori, Cesar O. Freytes, Gerhard C. Hildebrandt, Usama Gergis, Sachiko Seo, Baldeep Wirk, Marcelo C. Pasquini, Bipin N. Savani, Mohamed L. Sorror, Edward A. Stadtmauer, Saurabh Chhabra

Summary: Noninfectious pulmonary toxicity (NPT) is a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), including idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP). This study found that severe pulmonary comorbidity, acute graft-versus-host disease, mismatched unrelated donor and cord blood transplantation, and HCT Comorbidity Index (HCT-CI) score >= 1 were risk factors for developing NPT, while alloHCT performed in 2014 or later, non-total body irradiation-based conditioning, and platelet recovery were associated with a decreased risk of NPT.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, Lisa Rybicki, Linda Mclellan, Jane Dabney, Aaron T. Gerds, Seth J. Rotz, Matt Kalaycio, Rabi Hanna, Betty K. Hamilton, Navneet S. Majhail, Ronald M. Sobecks

Summary: This study compared the HRQOL between haplo-HCT and other donor sources for HCT, showing no difference in some aspects but differences in specific situations. Haplo-HCT demonstrated better emotional and functional well-being in certain conditions.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

暂无数据